Excess Mortality in Polycythemia Vera and Essential Thrombocythemia

Management of polycythemia vera and essential thrombocythemia.

The optimal management of patients with polycythemia vera (PV) and essential thrombocythemia (ET) continues to be controversial. Both diseases present diagnostic challenges and there is a paucity of data from randomized clinical trials to guide therapeutic decisions. However, the past two years have seen major advances in our understanding of these myeloproliferative disorders (MPD). First, the...

Platelet activation and inhibition in polycythemia vera and essential thrombocythemia.

Persistently enhanced platelet activation has been characterized in polycythemia vera (PV) and essential thrombocythemia (ET) and shown to contribute to a higher risk of both arterial and venous thrombotic complications. The incidence of major bleeding complications is also somewhat higher in PV and ET than in the general population. Although its efficacy and safety was assessed in just 1 relat...

Oligoarray comparative genomic hybridization in polycythemia vera and essential thrombocythemia.

| 1098 | haematologica | 2008; 93(7) lower than the wild-type, which is consistent with the low circulating levels of the abnormal chain (Figure 2B). These data demonstrate that this point mutation is associated to a severe reduction of the mutant mRNA expression level, which causes a β-thalassemia phenotype by eliciting β-globin chain deficiency. The molecular mechanisms responsible for impair...

Prevention of thrombosis in polycythemia vera and essential thrombocythemia.

Anagrelide-associated cardiomyopathy in polycythemia vera and essential thrombocythemia.

A comprehensive database inquiry at our institutions identified 11 patients with echocardiogram-documented idiopathic cardiomyopathy that post-dated a diagnosis of either polycythemia vera or essential thrombocythemia. Anagrelide therapy was temporally associated with the particular complication in 6 patients, all of whom experienced symptomatic and/or objective improvement after drug discontin...